ANIMATION

Apoptosis and BCL-2

Share this animation:

ABT-199/GDC-0199 is a small molecule drug in co-development by Abbvie and Genentech for the selective inhibition of BCL-2, a key regulator of cellular apoptosis. BCL-2, part of the larger BCL-2 family, is responsible for the sequestration of pro-apoptopic proteins along the mitochondrial membrane. Displacement of these proteins from BCL-2 in cancerous cells may prime these cells for apoptosis.

Share It:
Contact XVIVO

Client


Abbvie; Genentech

Through their creative prowess and technical mastery, XVIVO is defining and redefining the very frontier of scientific animation. As science and medicine explore increasingly remote realms, their work provides a vital link allowing researchers and the general public to grasp visually an astonishing landscape of new possibilities.

Brian Greene, Professor Mathematics & Physics, Columbia University
Share this animation: